Qiagen QCI Interpret One Software, QiaSeq Pan-Cancer Multimodal Panel; QiaSeq Targeted Methyl Panel
Qiagen launched multiple new products for genomic variation analysis in connection with the virtual 2020 American Society of Clinical Oncology annual meeting.
Qiagen's new QCI Interpret One software joins the company's Qiagen Clinical Insights portfolio, and provides variant- and disease-specific evidence for every variant in any somatic panel, backing each classification with the latest peer-reviewed publications, oncologist-reviewed interpretation summaries, and "expert second opinions," the company said. The new product combines the former N-f-One interpretation summaries with Qiagen's QCI Interpret structured variant interpretation database, the company noted.
Meanwhile, the new QiaSeq Pan-cancer Multimodal panel enables the consolidation of two separate next-generation sequencing-based DNA and RNA variant profiling workflows into one. It also enables scalable and parallel integration of up to thousands of targets in one enrichment step in a single tube, Qiagen said. Ideal for comprehensive genomic profiling and biomarker discovery, this 1.44-Mb panel consists of more than 600 target genes and fusions involved in the onset, progression, and treatment response across different cancer types, as well as microsatellite instability markers. Qiagen said the panel has a one-day turnaround time.
Finally, the new QiaSeq Targeted Methyl panels provide NGS-based targeted methylation analysis with a one-day turnaround time using the company's proprietary single primer extension technology. Qiagen offers predesigned panels for breast and colorectal cancer, as well as rapid, online custom design capabilities to create tailored panels for customer-specific applications. The company expects to launch immuno-oncology and T-cell infiltration applications later in 2020.
Thermo Fisher Scientific Orbitrap Exploris Mass Spectrometers, Proteome Discoverer 2.5 Software, Xcalibur 4.4 Software
Thermo Fisher Scientific has released the Thermo Scientific Orbitrap Exploris 240 and 120 mass spectrometers. The Exploris 240 is designed for researchers working in proteomics, metabolomics, biopharmaceutical characterization, and small-molecule analysis. It promises discovery and identification with increased accuracy and offers operational simplicity and streamlined time-to-result. The system delivers mass accuracy, sensitivity, and resolving power across a wide dynamic range. It offers positive/negative-mode switching for comprehensive sample coverage and fast scan speeds.
The Exploris 120 offers internal calibration for consistent data quality and decision making. It features fast scanning modes and rapid polarity switching for comprehensive sample coverage and increased productivity.
In addition, the company launched the Thermo Scientific Proteome Discoverer 2.5 software for higher-confidence peptide identification, more accurate quantification, and higher-throughput data analysis of proteomics data. It uses deep learning to more accurately predict fragmentation mass spectra, facilitated by a Prosit-derived neural network licensed from bioinformatics firm and collaborator MSAID. It also provides more confident results in applications that require large search spaces, such as human leukocyte antigen (HLA) or metaproteomic analyses. In addition, the new release includes an enrichment service that helps provide biological meaning for differential analyses and support of targeted workflows. It also has tools to help deploy Thermo Scientific SureQuant Targeted Mass Spectrometry Assay Kits and custom SureQuant IS-triggered acquisition assays in new proteomics labs.
The company also launched the Thermo Scientific Xcalibur 4.4 software, which brings the AcquireX intelligent data acquisition workflow to Thermo Scientific Orbitrap Exploris mass spec platform users. It enables the fully automated collection of high-quality MS/MS data on components of interest in a sample and reduces manual input and the need for repeat runs.
Bruker MALDI-2 Source for TimsTOF Flex; 4D Proteomics Workflows
Bruker has launched the MALDI-2 post-ionization source as an option on its TimsTOF Flex ESI/MALDI mass spectrometer. The new technology can offer one or two orders of magnitude higher sensitivity for many small molecules and lipids, increasing the range of applications of MALDI mass spectrometry and imaging. MALDI-2 requires a second laser (266 nm) fired orthogonally into the expanding MALDI plume that is generated by Bruker's proprietary primary SmartBeam 3D (355 nm) laser. An optimized FlexMatrix formulation is recommended for MALDI-2, the company said.
Bruker has also launched TIMS/PASEF-enabled 4D proteomics methods that leverage the large-scale, real-time availability of accurate collision cross sections for tens of thousands of measured peptides per 4D nanoLC-CCS-MS/MS run. These new methods and software include prm-PASEF, short-gradient dia-PASEF, MOMA, and "run and done" proteomics using a novel GPU-based real-time search engine. The new innovations enable enhanced peptide, protein, and PTM identification; sustained, ultra-high sensitivity LFQ performance; and truly high-throughput methods for 4D proteomics, 4D lipidomics, and 4D metabolomics on the TimsTOF Pro platform, Bruker said.
For more new products and services, please visit the New Products page on our website.